
[Federal Register Volume 77, Number 197 (Thursday, October 11, 2012)]
[Notices]
[Pages 61768-61769]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24974]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]


Neurological Devices Panel of the Medical Devices Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Neurological Devices Panel of the Medical 
Devices Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on November 1, 2012, from 8 
a.m. to 6 p.m.
    Location: Hilton, Washington, DC North/Gaithersburg, Grand 
Ballroom, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel's 
telephone number is 301-977-8900.
    Contact Person: LCDR Avena Russell, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 66, rm. 1535, Silver Spring, MD 20993-0002, 301-796-3805, 
Avena.Russell@fda.hhs.gov, or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in 
the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    Agenda: On November 1, 2012, the committee will discuss current 
knowledge about the safety and effectiveness of the CoAxia NeuroFlo 
Catheter device for the intended use of diverting cardiac output to the 
cerebral vasculature via partial occlusion of the descending aorta, 
including in patients with acute ischemic stroke within 14 hours of 
symptom onset.
    The CoAxia NeuroFlo Catheter is a 7F multi-lumen device with two 
balloons mounted near the distal tip. The proximal end has a multi-port 
manifold which provides access for the guidewire, monitoring of blood 
pressure, and independent inflation of the individual balloons. The 
device is placed in the descending aorta. On March 30, 2005, a 
Humanitarian Device Exemption application for the CoAxia NeuroFlo 
Catheter was approved for the following indication for use:

    The CoAxia NeuroFlo Catheter is intended for the treatment of 
cerebral ischemia resulting from symptomatic vasospasm following 
aneurismal subarachnoid hemorrhage (SAH), secured by either surgical 
or endovascular intervention for patients who have failed maximal 
medical management.

    Of note, the CoAxia Neuroflo Catheter is identical in design to the 
Coaxia FloControl which is currently cleared for the following general 
indications for use:
     The CoAxia FloControl Catheter is intended for use in 
selectively stopping or controlling flow in the peripheral vasculature 
(K023914).
     The CoAxia FloControl Catheter is intended for use in 
selectively stopping or controlling flow in the peripheral vasculature, 
which includes the descending aorta (K090970).
    CoAxia has submitted a de novo application for the NeuroFlo 
Catheter for the following indication:

    The CoAxia NeuroFlo Catheter is intended for use in diversion of 
cardiac output via partial occlusion of the descending aorta, 
including patients with acute ischemic stroke within 14 hours of 
symptom onset. The CoAxia NeuroFlo Catheter is also intended for use 
in selectively stopping or controlling blood flow in the peripheral 
vasculature, which includes the descending aorta.

    FDA is convening this committee to seek expert scientific and 
clinical opinion on the risks and benefits of this device based on the 
available premarket and postmarket data. In particular, the panel will 
be asked to discuss the safety and effectiveness data from the ``Safety 
and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)'' 
clinical trial

[[Page 61769]]

as they relate to the proposed indications for use.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
October 16, 2012. Oral presentations from the public will be scheduled 
between approximately 1 p.m. and 2 p.m. Those individuals interested in 
making formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before October 5, 2012. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by October 9, 2012.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Ann Marie Williams, 
Committee Management Staff, 301-796-5966 at least 7 days in advance of 
the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: October 3, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-24974 Filed 10-10-12; 8:45 am]
BILLING CODE 4160-01-P


